Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab as part of reduced-intensity conditioning for high-risk chronic lymphocytic leukemia undergoing allogeneic hematopoietic progenitor transplantation
2010-024467-40Phase 2Completed
- Sponsor
- Grupo Español de Trasplante Hematopoyético
- Start
- Jul 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ofatumumab in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Grupo Español de Trasplante Hematopoyético. Primary endpoint: Progression-free survival at 3 years. Started Jul 2011; status: completed.
02
Drugs
ofatumumab
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2010-024467-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024467-40.